Premium
Altered immunoglobulin E diversity and regulation of allergic inflammation in asthma
Author(s) -
Davies J. M.
Publication year - 2009
Publication title -
clinical and experimental allergy
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.462
H-Index - 154
eISSN - 1365-2222
pISSN - 0954-7894
DOI - 10.1111/j.1365-2222.2009.03231.x
Subject(s) - immunoglobulin e , omalizumab , immunology , cd23 , allergy , antigen , medicine , allergic inflammation , antibody
The clinical efficacy of anti-immunoglobulin E (IgE)\udtherapy indicates a central role for IgE in perpetuation of\udallergic inflammatory diseases. Omalizumab is now uti-\udlized in treatment of a wide variety of allergic conditions\udincluding severe asthma, allergic rhinitis, atopic dermati-\udtis, food allergy and urticaria either alone or adjunct with\udother therapies such as steroid administration or allergen-\udspecific immunotherapy [1, 2]. Current research activity is\udfocused on the cellular and molecular mechanisms by\udwhich IgE influences the immunopathogenesis of allergic\uddisease [3]. Increased knowledge of how IgE exerts its\udeffects will underpin effective clinical use of anti-IgE\udtreatment. In this issue Kerzel et al. [4] investigate the\udeffects of altered antibo dy repertoire on the outcomes of\udan experimental model of allergic asthma